XML 32 R16.htm IDEA: XBRL DOCUMENT v3.26.1
OTHER BALANCE SHEET COMPONENTS
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OTHER BALANCE SHEET COMPONENTS OTHER BALANCE SHEET COMPONENTS
Table 8.1: Details of Other Current Assets
As of December 31,
20252024
(in thousands)
Inventories, net$996 $1,783 
Deferred costs887 573 
Receivables - other529 210 
Other1,250 10 
Other current assets$3,662 $2,576 
Table 8.2: Details of Other Assets
As of December 31,
20252024
(in thousands)
Investment (1)
$3,750 $3,000 
Prepaid expenses and deferred commission – long-term portion537 4,975 
Restricted cash140 139 
Other86 75 
Other assets$4,513 $8,189 
(1) In March 2024, the Company made a $3.0 million investment in a privately-held company via a simple agreement for future equity ("SAFE"). During fiscal year 2024, the Company elected to apply the fair value option ("FVO") for its SAFE investment, as the Company believes the FVO best reflects the economics of the underlying transaction. In October 2025, the Company's SAFE investment was settled into 8,964,262 shares of Series A common stock at a settlement price of $0.42 per share, based on the valuation cap in the original agreement, resulting in 3.8% ownership with no significant influence over the privately-held company. Upon settlement of the SAFE in fiscal year 2025, the investment was remeasured to its fair value of $3.8 million, and a fair value adjustment of $0.8 million was recorded within "Other income" on the consolidated statements of operations. Effective October 2025, the SAFE investment was settled into equitable shares of the privately-held company's common stock. The investment does not have a readily determinable fair value and the Company elected the measurement alternative to value its investment. The fair value of this investment was based on non-marketable observable inputs, which represent Level 3 measurement within the fair value hierarchy. The investment was carried at cost less impairment, if any, and subsequently measured to fair value upon observable price changes in an orderly transaction for the identical or similar investments of the same issuer, with any gains or losses recorded within "Other income" on the consolidated statements of operations.
Table 8.3: Details of Accrued Liabilities
As of December 31,
20252024
(in thousands)
Accrued project expenses$4,289 $3,238 
Restructuring expenses accrual 1,451 37 
Other1,160 1,174 
Accrued liabilities$6,900 $4,449